fexofenadine
fexofenadine: developed by 2 companies · 5 clinical trials tracked · 6 FDA decisions.
fexofenadine evidence translation
What we can confirm
6 FDA records · 5 tracked trials
What it means
What to watch
Prepared research question
What is verified about fexofenadine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
| Sanofi (SNY) Uses temporarily relieves these symptoms due to hay fever or… | Approved |
Clinical Trials (5)
A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants
Primary endpoint: Part 1/1a: Geometric mean ratio (GMR) of Maximum observed plasma concentration (Cmax) of midazolam with and without KarXT
A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs)
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
Primary endpoint: Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 Infusions
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Primary endpoint: Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Primary endpoint: Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 24
FDA Decisions6 records
Frequently asked questions
Who is developing fexofenadine?
fexofenadine is being developed by DR REDDYS LABORATORIES LTD, Sanofi.
How many clinical trials involve fexofenadine?
BioSniper tracks 5 clinical trials involving fexofenadine.
What is fexofenadine's latest FDA decision?
The most recent tracked FDA decision for fexofenadine is Approval for Use(s) temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat temporarily relives nasal congestion due to the common cold, hay fever or other upper respiratory allergies reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose, dated May 31, 2022.